Literature DB >> 6766152

The relative merits of cromolyn sodium and high-dose theophylline therapy in childhood asthma.

S Godfrey.   

Abstract

The use of cromolyn sodium (SCG) and high-dose theophylline (HDT) in the treatment of chronic perennial asthma in children is reviewed. It is noted that the regimens are only suitable for children with persistent symptoms uncontrolled by simpler forms of treatment. The methods of administration and dosage based on pharmacologic data are considered, and the potential importance of long-acting theophylline and nebulized cromolyn preparations is noted. Short-term studies have confirmed the efficacy of both drugs, and a comparative study showed little difference between them. Long-term studies of SCG have demonstrated its value to some 66% of children without serious side effects. No formal long-term studies have been carried out on HDT. Side effects from theophylline can often be eliminated by careful control of blood levels. From published evidence, neither SCG nor HDT is effective in steroid-dependent asthmatic children, and they contribute little, if anything, to management in such cases. The difference in cost of the drugs is small when all factors are considered, and either regimen is justified by the saving in medical expenses when used for carefully selected patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6766152     DOI: 10.1016/0091-6749(80)90192-x

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  3 in total

Review 1.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

Review 2.  Cromolyn.

Authors:  B A Berman; R N Ross
Journal:  Clin Rev Allergy       Date:  1983-03

3.  Nebulised cromoglycate, theophylline, and placebo in preschool asthmatic children.

Authors:  J Glass; L N Archer; W Adams; H Simpson
Journal:  Arch Dis Child       Date:  1981-08       Impact factor: 3.791

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.